Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial

被引：3
|
作者：
Byrne, E
机构：
来源：
NEUROLOGY | 2003年 / 60卷 / 11期
关键词：
D O I：
10.1212/WNL.60.11.1872
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1872 / 1872
页数：1
相关论文
共 50 条
  • [31] PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update
    Reuss, Reinhard
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 131 - 138
  • [32] Comparative Toxicity of Interferon Beta-1a Impurities of Heavy Metal Ions
    Berillo, Dmitriy
    MEDICINA-LITHUANIA, 2022, 58 (04):
  • [33] Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
    Chitnis, Tanuja
    Arnold, Douglas L.
    Banwell, Brenda
    Brueck, Wolfgang
    Ghezzi, Angelo
    Giovannoni, Gavin
    Greenberg, Benjamin
    Krupp, Lauren
    Rostasy, Kevin
    Tardieu, Marc
    Waubant, Emmanuelle
    Wolinsky, Jerry S.
    Bar-Or, Amit
    Stites, Tracy
    Chen, Yu
    Putzki, Norman
    Merschhemke, Martin
    Gaertner, Jutta
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11): : 1017 - 1027
  • [34] Rebif - Interferon beta-1a - SERONO - Second interferon beta-1a product for relapsing multiple sclerosis
    不详
    FORMULARY, 2002, 37 (04) : 169 - 169
  • [35] Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
    Bovis, Francesca
    Kalincik, Tomas
    Lublin, Fred
    Cutter, Gary
    Malpas, Charles
    Horakova, Dana
    Havrdova, Eva Kubala
    Trojano, Maria
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Onofrj, Marco
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Eichau, Sara
    Patti, Francesco
    Terzi, Murat
    Grammond, Pierre
    Bergamaschi, Roberto
    Sola, Patrizia
    Ferraro, Diana
    Ozakbas, Serkan
    Iuliano, Gerardo
    Boz, Cavit
    Hupperts, Raymond
    Grand'Maison, Francois
    Oreja-Guevara, Celia
    van Pesch, Vincent
    Cartechini, Elisabetta
    Petersen, Thor
    Altintas, Ayse
    Soysal, Aysun
    Ramo-Tello, Cristina
    McCombe, Pamela
    Turkoglu, Recai
    Butzkueven, Helmut
    Wolinsky, Jerry S.
    Solaro, Claudio
    Sormani, Maria Pia
    NEUROLOGY, 2021, 96 (02) : E214 - E227
  • [36] Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
    Unsal, Mirac Aysen
    TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (01) : 50 - 51
  • [37] Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a
    MacMillan, Erin L.
    Schubert, Julia J.
    Vavasour, Irene M.
    Tam, Roger
    Rauscher, Alexander
    Taylor, Carolyn
    White, Rick
    Garren, Hideki
    Clayton, David
    Levesque, Victoria
    Li, David K. B.
    Kolind, Shannon H.
    Traboulsee, Anthony L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (04)
  • [38] Prevention of chronic black holes with interferon beta-1a in secondary progressive MS
    Traboulsee, A
    Zhao, G
    Cheng, Y
    Li, D
    MULTIPLE SCLEROSIS, 2005, 11 : S76 - S76
  • [39] Quality-of-life assessment in patients with MS receiving interferon beta-1a: a comparative longitudinal study of Avonex and its biosimilar Cinnovex
    Abolfazli, R.
    Hosseini, A.
    Gholami, K.
    Javadi, M. R.
    Torkamandi, H.
    Emami, S.
    JOURNAL OF NEUROLOGY, 2012, 259 : S111 - S112
  • [40] Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS
    Kümpfel, T
    Bergh, FT
    Pollmächer, T
    Holsboer, F
    Trenkwalder, C
    NEUROLOGY, 2000, 55 (08) : 1231 - 1233
12345